CDKN2A and benign ovarian sex cord-stromal tumor: Na et al[39] analyzed the immunohistochemical p16 expression in the peri-tumoral stroma of primary and recurrent aGCTs, found primary aGCTs had significantly higher stromal p16 expression levels than nonpathological ovaries and benign sex cord-stromal tumors, recurrent aGCTs showed significantly elevated levels of stromal p16 expression compared to primary tumors, suggested stromal p16 expression might be involved in the development and progression of aGCTs.